Pregabalin for the treatment of postherpetic neuralgia

By R. Dworkin, A. Corbin, J. Young, U. Sharma, L. LaMoreaux, H. Bockbrader, E. Garofalo, R. Poole. Neurology, 2003

828 citations recorded by the source corpus.

Subfields: Epidemiology, Physiology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/9fffad4610007d4a950248ebbd7276618bc5db89

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. Alec B. O’Connor
2. T. S. Jensen
3. N. Finnerup
4. S. Sindrup
5. Clifford J. Woolf

Citations in the corpus

• Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies (2008, background): “The drug is not bound to serum proteins (Vd, 0.9 L/kg), it is not metabolized and it is eliminated unchanged renally (Vollmer et al., 1988).”
• Core outcome measures for chronic pain clinical trials: IMMPACT recommendations (2003, background): “…that can be compared across different conditions and studies; diseasespecific measures assess problems associated with specific conditions that may not be assessed by generic measures and may also be more responsive to the effects of treatment (e.g. Dworkin et al., 2001; Guyatt et al., 1993).”
• Pharmacologic management of neuropathic pain: Evidence‐based recommendations (2007, background): “RCTs have demonstrated significantly greater pain relief with lidocaine patch 5% than with vehicle-controlled patches in patients with PHN and allodynia [34,95] and in patients with diverse peripheral NP conditions and allodynia [72], including a subgroup without PHN [71].”
• The evidence for pharmacological treatment of neuropathic pain (2010, background): “in four pregabalin studies in PHN and painful diabetic neuropathy [24,60,100,108] the combined NNT for 30% is 3.”
• A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin (2010, neutral): “Each shaded area corresponds to 95% of the predicted interval for the mean pain score reduction with the drug, and the thick black lines represent the 50th percentile of the predicted mean pain score reduction.([38-44]) 666 Bockbrader et al.”
• Algorithm for neuropathic pain treatment: An evidence based proposal (2005, neutral): “However, onset of pain relief with pregabalin can be more rapid than with gabapentin because its starting dosage of 150 mg/day is efficacious [26].”
• Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double‐blind, placebo‐controlled trial (2004, methodology): “Pregabalin has shown efficacy in the treatment of neuropathic pain associated with diabetes mellitus (Sharma et al., 2000) and postherpetic neuralgia (Dworkin et al., 2003), two well-studied neuropathic pain syndromes.”